euro adhoc: Intercell AG / other / US Defense Logistics Agency announces plans to enter into supply contract to purchase Japanese Encephalitis vaccine » Request for Proposal (RFP) aiming at exclusi

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

21.08.2008

Vienna (Austria), August 21, 2008 - Intercell AG (VSE: ICLL)
announced that the Defense Logistics Agency (DLA), United States
Department of Defense, has posted today a Request for Proposal (RFP)
for purchase of Japanese Encephalitis (JE) vaccine. As JE is a
serious and growing public health threat in Asia, the DLA intends to
enter into a contract to purchase supplies of JE vaccine for use with
military personnel who are deployed to affected countries.

The major details of this RFP are as follows:

» Exclusive contract to supply DLA with their requirements for JE
vaccine

» Multiyear contract, with annual options to facilitate price and
quantity modifications

» Duration of contract will be 5 years, at minimum

Intercell has already been in close contact with the DLA regarding
this RFP and believes one reason for this proposed contract at this
time is the pending Biological License Application (BLA) with the US
Food and Drug Administration (FDA) for Intercell´s JE vaccine.
Intercell submitted the BLA for its JE vaccine in December 2007 and
anticipates FDA approval and subsequent first sales to the military
markets in the next few months.

"We are pleased that the DLA has announced this RFP to establish a
contract for supply of JE vaccine," stated Gerd Zettlmeissl, Chief
Executive Officer of Intercell. "Intercell´s JE vaccine was developed
in collaboration with the Walter Reed Army Institute (US Department
of Defense) and we look forward to continuing this valued
relationship by securing a long-term, exclusive contract for supply
of the vaccine for use in the military´s JE immunization program.
Intercell plans to respond to this RFP in a timely manner and we are
optimistic that we can successfully close a contract in due time."

Japanese encephalitis, a mosquito-borne flaviviral infection, remains
virulent in Asia and has recently spread to countries not previously
infected. Hence, the virus is a constant health threat to millions of
civilian travelers and military personnel visiting or being deployed
to affected countries, including China and India. There is no
treatment for JE, so vaccination is the primary countermeasure
against this disease.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Communications

Tel. +43 1 20620-303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market